[go: up one dir, main page]

MX2010005048A - Acido 4-[4-(2-adamantilcarbamoil)-5-terc-butil-pirazol-1-il]benzoi c-465. - Google Patents

Acido 4-[4-(2-adamantilcarbamoil)-5-terc-butil-pirazol-1-il]benzoi c-465.

Info

Publication number
MX2010005048A
MX2010005048A MX2010005048A MX2010005048A MX2010005048A MX 2010005048 A MX2010005048 A MX 2010005048A MX 2010005048 A MX2010005048 A MX 2010005048A MX 2010005048 A MX2010005048 A MX 2010005048A MX 2010005048 A MX2010005048 A MX 2010005048A
Authority
MX
Mexico
Prior art keywords
adamantylcarbamoyl
pyrazol
tert
butyl
benzoic acid
Prior art date
Application number
MX2010005048A
Other languages
English (en)
Inventor
James Stewart Scott
Paul Robert Owen Whittamore
Martin Packer
Andrew Stocker
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2008/000454 external-priority patent/WO2008099145A1/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2010005048A publication Critical patent/MX2010005048A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

El ácido 4-[4-(2-adamantilcarbamoil)-5-terc-butil-pirazol-1-il]ben zoico y saltes farmacéuticamente aceptables del mismo y una forma cristalina particular de agente (Forma 1); su uso en la inhibición de 11 ßHSD1, proceso para fabricarlo y composiciones farmacéuticas que lo comprenden también se describen.
MX2010005048A 2007-11-06 2008-11-05 Acido 4-[4-(2-adamantilcarbamoil)-5-terc-butil-pirazol-1-il]benzoi c-465. MX2010005048A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US98573507P 2007-11-06 2007-11-06
PK10808 2008-02-04
PCT/GB2008/000454 WO2008099145A1 (en) 2007-02-12 2008-02-11 Pyrazole derivatives as 11-beta-hsd1 inhibitors
US8230408P 2008-07-21 2008-07-21
PCT/GB2008/051029 WO2009060232A1 (en) 2007-11-06 2008-11-05 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid - 465

Publications (1)

Publication Number Publication Date
MX2010005048A true MX2010005048A (es) 2010-07-28

Family

ID=42759138

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005048A MX2010005048A (es) 2007-11-06 2008-11-05 Acido 4-[4-(2-adamantilcarbamoil)-5-terc-butil-pirazol-1-il]benzoi c-465.

Country Status (17)

Country Link
US (1) US20110060022A1 (es)
EP (1) EP2217232A1 (es)
JP (1) JP2011502978A (es)
KR (1) KR20100095439A (es)
CN (1) CN101909621A (es)
AU (1) AU2008326226B2 (es)
BR (1) BRPI0819177A2 (es)
CA (1) CA2703781A1 (es)
CO (1) CO6270318A2 (es)
CR (1) CR11415A (es)
DO (1) DOP2010000135A (es)
EA (1) EA201000701A1 (es)
EC (1) ECSP10010159A (es)
IL (1) IL205455A0 (es)
MX (1) MX2010005048A (es)
WO (1) WO2009060232A1 (es)
ZA (1) ZA201003031B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2630665C (en) 2005-11-21 2011-03-15 Shionogi & Co., Ltd. Heterocyclic compound having inhibitory activity on 11-.beta.-hydroxysteroid dehydrogenase type i
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) * 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
WO2008142986A1 (ja) 2007-05-18 2008-11-27 Shionogi & Co., Ltd. Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有する含窒素複素環誘導体
CN101969946A (zh) * 2008-02-04 2011-02-09 阿斯利康(瑞典)有限公司 4-[4-(2-金刚烷基氨基甲酰基)-5-叔丁基-吡唑-1-基]苯甲酸的新晶型
AU2009239794A1 (en) * 2008-04-22 2009-10-29 Astrazeneca Ab Substituted pyrimidin-5-carboxamides 281

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1492541A1 (en) 2002-04-05 2005-01-05 The University Of Edinburgh Pharmaceutical compositions comprising a 11-beta hydroxysteroid dehydrogenase inhibitor and a diuretic agent
WO2004089470A2 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S New amide derivatives and pharmaceutical use thereof
WO2006132436A1 (ja) * 2005-06-08 2006-12-14 Japan Tobacco Inc. 複素環化合物

Also Published As

Publication number Publication date
CR11415A (es) 2010-08-27
BRPI0819177A2 (pt) 2015-05-05
WO2009060232A1 (en) 2009-05-14
CA2703781A1 (en) 2009-05-14
ECSP10010159A (es) 2010-06-29
EA201000701A1 (ru) 2010-12-30
CO6270318A2 (es) 2011-04-20
JP2011502978A (ja) 2011-01-27
KR20100095439A (ko) 2010-08-30
US20110060022A1 (en) 2011-03-10
IL205455A0 (en) 2010-12-30
AU2008326226B2 (en) 2011-10-20
DOP2010000135A (es) 2010-06-30
CN101909621A (zh) 2010-12-08
ZA201003031B (en) 2011-10-26
EP2217232A1 (en) 2010-08-18
AU2008326226A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
MX2010008583A (es) Novedosos formas cristalinas de acido 4-[4-(2-adamantilcarbamoil)- 5-ter-butil-pirazol-1-il]benzoico.
MY144209A (en) Pyridazine derivatives as 11beta-hydroxysteroid dehydrogenase type 1 inhibitors
NO20070458L (no) Aryl-pyridinderivater som 11-Beta-HSD1 inhibitorer
IN2012DN03337A (es)
MX2011012017A (es) Nuevos derivados azaciclicos como inhibidores de lipasa sensible a las hormonas (hsl).
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten
MX2009008506A (es) Derivados del pirazol como inhibidores de 11-b-hsd1.
NO20071593L (no) Pyrimidinderivater
NO20091548L (no) Imidazolon- og imidazolidinonderivater som 11B-HSD1 inhibitorer for diabetes
MX2009013078A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotropicos de glutamato - 842.
UA90742C2 (en) Pyrazolone derivatives
MX2010005048A (es) Acido 4-[4-(2-adamantilcarbamoil)-5-terc-butil-pirazol-1-il]benzoi c-465.
UA105057C2 (uk) Композиція 1-[2-(2,4-диметилфенілсульфаніл)феніл]-піперазину
MX2008016426A (es) Derivados de alquilpiridazina como inhibidores de 11 beta hidroxiesteroide deshidrogenasa tipo 1(11b-hsd 1).
WO2009068468A3 (en) Pyridine compounds
ZA200806778B (en) N-Hydroxyacrylamide compounds
MX2009003169A (es) Derivados de sulfonamida.
IN2012DN01232A (es)
MY139522A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes
WO2008015139A3 (en) Inhibitors of zinc proteases thioaryl substituted and their use
WO2009106599A3 (en) Substituted piperidines as therapeutic compounds
MX2010010876A (es) Piperidinas sustituidas como compuestos terapeuticos.
MX2009013003A (es) Derivados de piperidina-amida.
MX2012002479A (es) Nuevos derivados de bencimidazol y su uso como agonistas del receptor x farnesoide.
MX2010004505A (es) Piperidinas 4,4-disustituidas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal